These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31467033)

  • 1. Consistent control of disease activity with fingolimod versus IFN β-1a in paediatric-onset multiple sclerosis: further insights from PARADIG
    Deiva K; Huppke P; Banwell B; Chitnis T; Gärtner J; Krupp L; Waubant E; Stites T; Pearce GL; Merschhemke M
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):58-66. PubMed ID: 31467033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of fingolimod on MRI outcomes in patients with paediatric-onset multiple sclerosis: results from the phase 3 PARADIG
    Arnold DL; Banwell B; Bar-Or A; Ghezzi A; Greenberg BM; Waubant E; Giovannoni G; Wolinsky JS; Gärtner J; Rostásy K; Krupp L; Tardieu M; Brück W; Stites TE; Pearce GL; Häring DA; Merschhemke M; Chitnis T;
    J Neurol Neurosurg Psychiatry; 2020 May; 91(5):483-492. PubMed ID: 32132224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relapse rates in patients with multiple sclerosis treated with fingolimod: Subgroup analyses of pooled data from three phase 3 trials.
    Derfuss T; Ontaneda D; Nicholas J; Meng X; Hawker K
    Mult Scler Relat Disord; 2016 Jul; 8():124-30. PubMed ID: 27456887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study.
    Cohen JA; Khatri B; Barkhof F; Comi G; Hartung HP; Montalban X; Pelletier J; Stites T; Ritter S; von Rosenstiel P; Tomic D; Kappos L;
    J Neurol Neurosurg Psychiatry; 2016 May; 87(5):468-75. PubMed ID: 26111826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study.
    Devonshire V; Havrdova E; Radue EW; O'Connor P; Zhang-Auberson L; Agoropoulou C; Häring DA; Francis G; Kappos L;
    Lancet Neurol; 2012 May; 11(5):420-8. PubMed ID: 22494956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
    Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
    Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxidative stress activity of fingolimod in multiple sclerosis.
    Yevgi R; Demir R
    Clin Neurol Neurosurg; 2021 Mar; 202():106500. PubMed ID: 33508648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada.
    Nakhaipour HR; Vudumula U; Khurana V; Sébire G; Mah JK; Pohl D; Schecter R; Adlard N
    J Med Econ; 2020 Dec; 23(12):1525-1533. PubMed ID: 33079578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fingolimod reduces the clinical expression of active demyelinating lesions in MS.
    Signoriello E; Landi D; Monteleone F; Saccà F; Nicoletti CG; Buttari F; Sica F; Marfia GA; Di Iorio G; Lus G; Centonze D
    Mult Scler Relat Disord; 2018 Feb; 20():215-219. PubMed ID: 29433094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of fingolimod in Hispanic patients with multiple sclerosis: pooled clinical trial analyses.
    Chinea Martinez AR; Correale J; Coyle PK; Meng X; Tenenbaum N
    Adv Ther; 2014 Oct; 31(10):1072-81. PubMed ID: 25245812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis.
    Chitnis T; Arnold DL; Banwell B; Brück W; Ghezzi A; Giovannoni G; Greenberg B; Krupp L; Rostásy K; Tardieu M; Waubant E; Wolinsky JS; Bar-Or A; Stites T; Chen Y; Putzki N; Merschhemke M; Gärtner J;
    N Engl J Med; 2018 Sep; 379(11):1017-1027. PubMed ID: 30207920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of switching from intramuscular interferon β-1a to oral fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS.
    Meng X; Chin PS; Hashmonay R; Zahur Islam M; Cutter G
    Contemp Clin Trials; 2015 Mar; 41():69-74. PubMed ID: 25545026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fingolimod therapy in early multiple sclerosis: an efficacy analysis of the TRANSFORMS and FREEDOMS studies by time since first symptom.
    Agius M; Meng X; Chin P; Grinspan A; Hashmonay R
    CNS Neurosci Ther; 2014 May; 20(5):446-51. PubMed ID: 24684973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.
    Lublin F; Miller DH; Freedman MS; Cree BAC; Wolinsky JS; Weiner H; Lubetzki C; Hartung HP; Montalban X; Uitdehaag BMJ; Merschhemke M; Li B; Putzki N; Liu FC; Häring DA; Kappos L;
    Lancet; 2016 Mar; 387(10023):1075-1084. PubMed ID: 26827074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
    Roskell NS; Zimovetz EA; Rycroft CE; Eckert BJ; Tyas DA
    Curr Med Res Opin; 2012 May; 28(5):767-80. PubMed ID: 22462530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uveitis in Patients with Multiple Sclerosis in Clinical Trials of Fingolimod: Incidence, Prevalence, and Impact on Disease Course.
    Lim LL; Silva DG; Lo TC; Pimentel RS; Butzkueven H; Hall AJ
    Ophthalmology; 2019 Mar; 126(3):438-444. PubMed ID: 30315901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-Term Effect of Immediate Versus Delayed Fingolimod Treatment in Young Adult Patients with Relapsing-Remitting Multiple Sclerosis: Pooled Analysis from the FREEDOMS/FREEDOMS II Trials.
    Ghezzi A; Chitnis T; K-Laflamme A; Meinert R; Häring DA; Pohl D
    Neurol Ther; 2019 Dec; 8(2):461-475. PubMed ID: 31325110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
    Traboulsee A; Li DKB; Cascione M; Fang J; Dangond F; Miller A
    BMC Neurol; 2018 Sep; 18(1):143. PubMed ID: 30217172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial.
    Comi G; Kappos L; Selmaj KW; Bar-Or A; Arnold DL; Steinman L; Hartung HP; Montalban X; Kubala Havrdová E; Cree BAC; Sheffield JK; Minton N; Raghupathi K; Ding N; Cohen JA;
    Lancet Neurol; 2019 Nov; 18(11):1009-1020. PubMed ID: 31492651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies.
    Haas J; Jeffery D; Silva D; Meier DP; Meinert R; Cohen J; Hartung HP
    Mult Scler Relat Disord; 2019 Nov; 36():101335. PubMed ID: 31557679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.